Ovarian cancer has a lot of new, interesting research emerging from research facilities.
This is an exciting time for those of us engaged in research and patient care for ovarian cancer. As we’ve learned more about this cancer – its early formation, molecular machinery, and the body’s defenses against it – we’ve also come to understand its weaknesses. An array of new therapies that target these vulnerabilities are now being developed and tested in clinical trials, many of them at Dana-Farber.
Our aim is to find which agents, in which combinations, work best in which patients.
One of the greatest recent advances was learning there are different subtypes of the disease, each with different risk factors, cells of origin, genomic profiles, aggressiveness, and treatment. Scientists at the Susan F. Smith Center for Women’s Cancers at Dana-Farber have also found that high-grade serous ovarian cancers – the most common type of ovarian cancer – often originate in the fallopian tubes.
These and other discoveries changed the course of research so that novel drugs are geared to patients with specific types of the disease, improving outcomes significantly.
We are now testing several categories of drugs in clinical trials, often in combination with one another, with chemotherapy, or as single agents.
Read Full Article: Ovarian Cancer: State of the Science – Insight
|Read Full Article: Ovarian Cancer: State of the Science – Insight|